Should transplantation still be considered for Ph1-negative myeloproliferative neoplasms in transformation?

ABSTRACT BCR-ABL negative myeloproliferative neoplasms (MPN) in transformation have a dismal prognosis, and allogeneic transplantation is thought to be the only curative therapeutic option. We retrospectively analyzed 53 molecularly annotated patients treated at Saint Louis Hospital (France), diagnosed between 2008 and 2018 with MPN in transformation. Median age was 65 years and median interval between MPN diagnosis and MPN transformation was 46 months. Median overall survival (OS) of the entire cohort after transformation was 7.1 months. Overall survival (OS) was better for patients treated by hypomethylating agents or by chemotherapy than those treated by best supportive care or single agent targeted therapy: 9.1 vs 1.5 months, p